Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership
03 January 2025 - 9:20AM
Edgar (US Regulatory)
Exhibit 99.1
Annex A
The Reporting Person currently
has the following outstanding options pursuant to the Issuer’s equity plans:
|
Date of option
grant |
Number of
shares |
Exercise Price
Per Share |
Vesting Schedule |
Expiration
Date |
Portion Vested at
12/23/2024 |
| 4/12/2022 |
7,143 |
$210 |
Vests in four equal annual installments beginning on
April 12, 2023. |
04/12/2032 |
3,572 |
| 10/26/2023 |
80,966 |
$5.75 |
Vests in four annual installments with 20% vesting
on each of October 26, 2024, 2025 and 2026 and 40% vesting on October 26, 2027. |
10/26/2033 |
16,193 |
| 12/09/2024 |
536,609 |
$0.78 |
Vests in four annual installments with 20% vesting
on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028. |
12/09/2034 |
— |
The vesting of the unvested options described above will increase the Reporting Person's beneficial ownership of Ordinary Shares.
Quoin Pharmaceuticals (NASDAQ:QNRX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Quoin Pharmaceuticals (NASDAQ:QNRX)
Historical Stock Chart
From Jan 2024 to Jan 2025
